Episode Description
The DEDICATE trial of TAVR vs SAVR, more on renal denervation, inclisiran, and marketing disguised as science are the topics John Mandrola, MD, discusses in today's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
I. TAVR vs SAVR
TAVI Comparable With SAVR in Lower-Risk Aortic Stenosis
- DEDICATE https://www.nejm.org/doi/full/10.1056/NEJMoa2400685
- Partner 3 https://www.nejm.org/doi/full/10.1056/NEJMoa1814052
- Evolut Low Risk https://www.nejm.org/doi/full/10.1056/NEJMoa1816885
- Barili meta-analysis https://doi.org/10.1093/ejcts/ezab516
II. Renal Denervation
Alcohol-Mediated Renal Denervation Promising in Hypertension
III. Inclisiran
Earlier Inclisiran Gives Better Long-Term LDL Reductions
- VICTORIAN INITIATE Trial https://www.jacc.org/doi/10.1016/j.jacc.2024.03.382
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.



























